Xconomy

AUGUST 22, 2019

The San Diego-based company’s experimental drug fosmetpantotenate failed a Phase 3 trial, FORT, in patients with a rare and deadly neurological disorder called pantothenate kinase-associated neurodegeneration, or PKAN.

San Diego 79

San Diego Study Marketing Develop 79

Xconomy

OCTOBER 1, 2018

VelosBio joined Johnson & Johnson’s JLABS @ San Diego incubator in January. The new VelosBio cash is earmarked for completing the work needed to proceed into human studies. The company is developing antibody drug conjugates, a class of cancer drug that links antibodies to potent cancer-fighting toxins.

San Diego 91

San Diego Incubator Class Study 91

Xconomy

APRIL 11, 2017

As part of the financing, Kalamazoo-based Octeta Therapeutics has been rechristened Cirius Therapeutics, and three San Diego-based biotech executives are stepping into key executive roles. All three were former Laguna Pharmaceuticals executives who spent the past 16 months scouting for Frazier as entrepreneurs-in-residence.

Study 55

Study San Diego Entrepreneur Venture Capital 55

Xconomy

APRIL 22, 2019

Swiss pharma giant Novartis has invested $75 million in a $142 million Series C round for San Diego-based Poseida, which is one of several companies developing what is meant to be a one-time, long-lasting treatment for multiple myeloma. Multiple myeloma affects about 300,000 Americans every year.

San Diego 83

San Diego Study Funding Invest 83

Xconomy

DECEMBER 20, 2018

New biopharma company Aristea Therapeutics has raised $15 million from Novo Holdings, the Danish investment company, and secured global rights to an investigational AstraZeneca drug that’s ready for Phase 2 study. The San Diego, CA, company made its public debut this week after starting up quietly earlier this year.

Develop 67

Develop Development San Diego Study 67

Xconomy

FEBRUARY 15, 2017

For these reasons, fatty liver disease is often called a “silent disease,” says Ariel Feldstein, a gastroenterologist at the University of California San Diego. Feldstein has been studying the liver for nearly 20 years, and his research now forms the basis of a newly launched company called Jecure Therapeutics.

UCSD 64

UCSD Press San Diego Class 64

Xconomy

AUGUST 1, 2017

Ciara Kennedy, who succeeded Mike Grey as Amplyx CEO late last year, said in an interview with Xconomy that the company plans to report results of its Phase 1 study at IDWeek, the annual infectious diseases conference that is set for early October in San Diego. But raising $67.

San Diego 67

San Diego Study Conference Report 67

Xconomy

DECEMBER 7, 2017

Proceeds will be used to advance Metacrine’s lead drug candidate, MET409, into first-in-human studies during the first half of 2018. Initial studies should be completed by the end of the year, the San Diego-based company said.

San Diego 49

San Diego Study Develop Development 49

Xconomy

SEPTEMBER 25, 2017

After launching a study to identify how tech hubs work, the leader of a nonprofit consortium created to boost Southern California’s startup ecosystem says he is focusing on three initiatives to supercharge the seven-county SoCal region as a hotbed for innovation. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Southern California 61

Southern California San Diego SoCal Incubator 61

Xconomy

JUNE 19, 2019

There’s a speed dating game of sorts happening as pharmaceutical companies that have approved cancer immunotherapies are testing their medications in combination with experimental drugs in hopes of reaching more patients.

Study 61

Study Activity Develop Development 61

Xconomy

FEBRUARY 14, 2020

Post-marketing studies aim to identify side effects not observed in the first three phases of testing. This week, results of such a study led to the market withdrawal of weight-loss pill lorcaserin (Belviq). But the post-marketing study revealed a higher incidence of.

Study 77

Study Marketing San Diego Blogging 77

Xconomy

JANUARY 9, 2019

The Boston company, which counts diabetes drug giants Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ) among its investors and partners, says the capital will support Phase 3 studies of its device this year, and if all goes well, an application for FDA approval. The cash tops off a Series B round of funding announced last year.

Study 87

Study Design Capital Startup 87

Xconomy

DECEMBER 21, 2018

Before you fly off, or drive, or simply unplug, check out our preview of what could be next year’s top clinical studies; the tumult in big pharma’s on again-off again relationship with consumer healthcare; big names on the move in the nation’s capital; and a flurry of year-end deals. Happy holidays, everyone.

Pricing 73

Pricing Sales Study News 73

Xconomy

FEBRUARY 22, 2017

The company, headquartered in Cranbury, NJ, disclosed this morning that it has raised a $74 million Series B round from Topspin Biotech Fund, Euclidian Capital, InterWest Partners, OrbiMed Advisors, and Osage University Partners. PMV raised a $30 million Series A in 2014. Read more » Reprints | Share:

Study 67

Study Startup Funding Capital 67

Xconomy

JULY 20, 2016

First came Inception Sciences , a holding company for spinning out biotech startups established by Versant Ventures and Peppi Prasit, the veteran San Diego drug developer. Dauntless says its simplified business structure is more capital-efficient, and there are important tax advantages for investors and other stakeholders.

San Diego 40

San Diego Avalon Outsource Development Newsletter 40

Xconomy

NOVEMBER 15, 2017

Acorda Therapeutics’ rebuilding plan just suffered another setback, leaving the fate of one of the experimental Parkinson’s disease drugs that is closest to market unclear.

Study 55

Study Report Marketing San Diego 55

Xconomy

AUGUST 17, 2016

and San Diego’s Avalon Ventures. Inbio Ventures, a venture capital management company, represented Pharmstandard in the deal. Avalon Ventures founded Avelas, and has housed the startup with other Avalon biotech startups at its COI Pharmaceuticals R&D facility in San Diego. Carmine Stengone.

Avalon 40

Avalon San Diego Study Invest 40

Xconomy

FEBRUARY 28, 2020

Making changes in the midst of the study was a no-no. Clinical trials have historically hewn to a rigid format. A trial is designed, conducted according to that design, and then results are analyzed. In recent years, regulators have showed openness to clinical trial designs intended to make drug testing more efficient.

News 89

News Design Study Examples 89

Xconomy

SEPTEMBER 27, 2016

Fortis Therapeutics, a new San Diego biotech, has raised $18 million in initial funding to develop drugs for hard-to-treat prostate and bone marrow cancers. San Diego’s Avalon Ventures led the Series A round, and has established Fortis at COI Pharma, the firm’s biotech incubator (which now houses 16 life sciences startups).

Avalon 40

Avalon Funding Startup San Diego 40

Xconomy

SEPTEMBER 7, 2016

Retrophin , the drug developer founded by controversial former biotech executive Martin Shkreli, has posted positive results from a midstage study for its treatment for a rare kidney disease. He licensed the drug from San Diego-based Ligand Pharmaceuticals (NASDAQ: LGND ) in March 2012. to $30 apiece.

San Diego 40

San Diego Pricing Study Journal 40

Xconomy

SEPTEMBER 6, 2019

In presenting clinical data from a Phase 3 study. If MedCo’s cholesterol-lowering drug inclisiran wins FDA approval, it will become the third entry in a new class of medicines that block a cholesterol-boosting protein called PCSK9. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 84

Pricing Class Study Marketing 84

Both Sides of the Table

APRIL 13, 2011

I owe ya’ a 20 minute call (or in person next time I’m in San Diego). Brad on blogging. How did you start blogging? “My Yeah, that was when I changed for me…” “…there was so much positive feedback on demystifying this one element of venture capital. Brad’s start in Venture Capital. was starting.

Venture Capital 288

Venture Capital Startup Technical Review Software Review 288

Xconomy

FEBRUARY 22, 2019

Intercept (NASDAQ: ICPT ) reported interim data from a Phase 3 study showing its drug, obeticholic acid (OCA), reduced liver scarring in NASH patients. This week, one company, Intercept Pharmaceuticals, solidified its lead. But how much will being first to the finish line mean when all is said and done?

News 86

News Study Report San Diego 86

Xconomy

AUGUST 17, 2016

Histogen, a San Diego-based regenerative medicine company with technology for growing skin cells and related products, said it has raised $6 million from an affiliate of Huapont Life Sciences, a healthcare products company based in Chongqing, China. Histogen claims that HSC triggers stem cells in the scalp to form hair.

Invest 40

Invest San Diego Journal Technical Review 40

Xconomy

JUNE 13, 2019

The new Series B round will give San Francisco-based BlackThorn—a startup spun out of the Scripps Research Institute in 2013—the backing to run human tests of two experimental treatments. The other, for autism, could start a Phase 1 study in 2020. Those plans. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Tool 78

Tool Study Research Startup 78

Xconomy

MAY 4, 2018

Here’s a case study of how fast things can change in biopharma. This week, Bristol-Myers Squibb, Merck, and AstraZeneca all curtailed plans to run additional studies with IDO blockers, adding to a recent, similar decision from Newlink Genetics. Major drug makers were dealing, too.

Case Study 52

Case Study Study Training Acquisition 52

Xconomy

JANUARY 30, 2018

Outside experts acknowledge that the studies were small but important. Reached this afternoon, Wilson called for close monitoring of patients receiving high doses of a certain type of gene therapy delivered into the bloodstream. The paper is getting the attention it deserves,” says Aravind Asokan, an associate.

Study 78

Study San Diego Company Companies 78

Xconomy

MARCH 17, 2017

The data, from a massive study of more than 27,000 patients, come at a time when drug and healthcare prices are a top U.S. political issue, and pricey new cholesterol drugs have been a key battleground.

Study 87

Study Pricing Sales Journal 87

Xconomy

APRIL 15, 2019

If a once-modest regional hospital and its new biotech allies have their way, the capital of Ohio could one day rival America’s other biomedical hubs. Our goal is to make Columbus the center of the universe for gene therapy,” says Doug Ingram, CEO of Sarepta Therapeutics.

Capital 111

Capital Startup San Diego Journal 111

Xconomy

APRIL 6, 2018

The FDA didn’t smile upon a big submission of depression studies from Alkermes, while those fighting liver disease got a mixed slate of data as a big medical conference looms. After the deals, we’ll move on to data. There were plenty of policy and drug-price headlines, Read more » Reprints | Share:

Study 55

Study Pricing Conference Marketing 55

Xconomy

AUGUST 1, 2016

Ionis (NASDAQ: IONS ) and its partner, Cambridge, MA-based Biogen (NASDAQ: BIIB ), this morning reported an interim look at an ongoing Phase 3 study of nusinersen—an RNA-based drug meant to help treat patients with SMA. Ionis will complete the ongoing Phase 3 studies before transitioning everything to Biogen.

Study 40

Study Research Statistics Help 40

Xconomy

SEPTEMBER 23, 2016

Of the options he faced at the time—forge ahead with the diagnostic tool despite adverse test results, close down the company and return the capital to investors, or come up with an alternative—Lim decided to pivot, and switched Ignyta’s focus from autoimmune diseases to cancer.

Study 40

Study Tool Technology Capital 40

Xconomy

NOVEMBER 19, 2018

You can enjoy. Read more » Reprints | Share:

Artificial Inteligence 74

Artificial Inteligence Education Study Organization 74

Xconomy

JULY 15, 2016

Our San Diego editor Bruce Bigelow penned a personal goodbye to entrepreneur Larry Bock, who died last week of pancreatic cancer at the age of 56. After last week’s revelation of three patient deaths in its leading cancer immunotherapy trial, the FDA suspended the study. The week started on a reflective note.

News 40

News Technical Review San Diego Startup 40

Xconomy

SEPTEMBER 20, 2019

Boston, San Francisco, and a few other metro areas might dominate the US life sciences, but some weeks, all bio-related eyes are on the nation’s capital. Health concerns about vaping continue to mount, and the feds could get involved.

Pricing 61

Pricing News Capital San Diego 61

Xconomy

JANUARY 24, 2017

That’s according to British recruitment firm Liftstream and its new study of biotech companies that went public in the recent boom years. If power in the business world is centered in the boardroom, women in biotech have a long way to go to get their fair share—and the venture community deserves much of the blame.

Report 40

Report Class Study Venture Capital 40

Xconomy

JANUARY 11, 2017

A recent study by EdSurge , an edtech information firm, shows venture funding for U.S. While we’re looking at venture deal numbers from the past year , let’s consider the education technology industry, which isn’t broken out by sector in the general reports I’ve seen. education tech companies totaled $1.03

Funding 40

Funding Education Venture Capital Study 40